Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020. This is a retrospective analysis of serological data, describing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli healthcare workers administrated the BNT162b2 vaccine. Seroconversion occurred by day 14 in all individuals, with IgG levels peaking approximately 30 days post inoculation. This study demonstrated the kinetics of the antibody response post vaccination with BNT162b2. The robustness of seroconversion was observed, alongside a statistically significant difference in IgG levels between employees over and younger 50 years of afge. Further research is required in order to examine the antibody kinetics overtime, as well as whether the age-dependent difference persists.

中文翻译：

---

BNT162b2疫苗接种后SARS-CoV-2抗-s IgG的动力学

BNT162b2 mRNA Covid-19疫苗已于2020年12月在以色列开始部署。这是对血清学数据的回顾性分析，描述了116名服用BNT162b2疫苗的以色列医护人员的SARS-CoV-2抗S IgG动力学。在所有个体中，血清转化发生在第14天，IgG水平在接种后约30天达到峰值。这项研究证明了BNT162b2疫苗接种后抗体反应的动力学。观察到血清转化的稳健性，以及50岁以上员工和年轻员工之间IgG水平的统计显着性差异。为了检查抗体动力学随时间变化以及年龄依赖性差异是否持续存在，需要进行进一步的研究。